ESTRO 2025 - Abstract Book

S1117

Clinical – Head & neck

ESTRO 2025

Results: Sixteen out of seventy patients were sarcopenic at baseline or developed sarcopenia during treatment. All of them were male. Twelve out of 16 sarcopenic patients underwent definitive RT. Median dose was 66.6 GyRBE. Chemotherapy (induction or/and concomitant) was administered in 50% of sarcopenic patients Among them, 68.75% had sinonasal cancer. Fifty-six patients developed a ≥ G2 acute toxicity (figure 2). In univariate analysis, SP was not related to higher treatment-related toxicity. No correlation were found between SP and MNA SF/NRS-2002 score as well as fatigue and BMI.

Conclusion: We observe a lower rate of sarcopenic pts compared to current literature. Despite the study’s limitations, our preliminary data indicate that sarcopenia is not associated with increased acute toxicity compared to non sarcopenic patients. This finding is likely owing to the physical selectivity of particle therapy. Further analyses will be performed to evaluate late toxicity and ouctcomes.

Keywords: sarcopenia, head and neck cancer, particle therapy

References: 1- Ganju RG et al. The impact of sarcopenia on tolerance of radiation and outcome in patients with head and neck cancer receiving chemoradiation. Radiother Oncol. 2019 Aug;137:117-124. doi:10.1016/j.radonc.2019.04.023. Epub 2019 May 11. PMID: 31085391. 2- Thureau S, et al. Prospective Evaluation of Sarcopenia in Head and Neck Cancer Patients Treated with Radiotherapy or Radiochemotherapy. Cancers (Basel). 2021 Feb 11;13(4):753. doi: 10.3390/cancers13040753. PMID: 33670339; PMCID: PMC7917983 3- Swartz JE et al. Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients. Oral Oncol. 2016 Nov;62:28-33. doi: 10.1016/j.oraloncology.2016.09.006. Epub 2016 Oct 3. PMID: 27865369